Drug Profile
Research programme: immunosuppressive therapeutics - Giuliani
Alternative Names: GED 0414Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Giuliani
- Developer Nogra Pharma
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunosuppression
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunosuppression in Italy
- 30 Apr 2008 Preclinical trials in Immunosuppression in Italy (unspecified route)